Oramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70%

Oramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70%

Source: 
Fierce Biotech
snippet: 

Oramed Pharmaceuticals’ dream of developing an oral insulin for type 2 diabetes looks to be over. With the candidate failing to beat placebo in a phase 3 trial, the biotech outlined plans to stop development and sent its share price tumbling in the process.